Document 0110
 DOCN  M94A0110
 TI    Fluconazole versus ketoconazole in the treatment of oropharyngeal
       candidiasis in HIV-infected children. Multicentre Study Group.
 DT    9412
 AU    Hernandez-Sampelayo T; Department of Pediatric Infectious Diseases,
       Hospital Infantil; Gregorio Maranon, Madrid, Spain.
 SO    Eur J Clin Microbiol Infect Dis. 1994 Apr;13(4):340-4. Unique Identifier
       : AIDSLINE MED/94349966
 AB    In an open multicentre study the efficacy and safety of fluconazole
       versus ketoconazole were evaluated in the treatment of 46 pediatric
       patients with oropharyngeal candidiasis and AIDS or HIV infection.
       Twenty-four subjects received oral fluconazole in a dosage of 3
       mg/kg/day and 22 subjects received oral ketoconazole in a dosage of 7
       mg/kg/day. The treatment duration ranged from 5 to 49 days. Results
       showed that fluconazole and ketoconazole have comparable efficacy and
       safety in the treatment of oropharyngeal candidiasis in HIV-infected
       children. Patients treated with fluconazole had higher clinical and
       mycological cure rates at the end of therapy (88% and 71% respectively)
       than those treated with ketoconazole (81% and 57% respectively). One
       case of drug-related side effects (diarrhea and abdominal pain) in a
       patient receiving ketoconazole resulted in discontinuation of treatment.
       Follow-up examinations 2 and 4 weeks post-treatment showed a comparably
       high rate of relapse in both patient groups.
 DE    Adolescence  Age Factors  AIDS-Related Opportunistic Infections/*DRUG
       THERAPY  Candida/ISOLATION & PURIF  Candidiasis, Oral/*DRUG
       THERAPY/MICROBIOLOGY  Child  Child, Preschool  Comparative Study  Female
       Fluconazole/*THERAPEUTIC USE  Human  Immunocompromised Host  Infant
       Infant, Newborn  Ketoconazole/*THERAPEUTIC USE  Male  Pharyngeal
       Diseases/*DRUG THERAPY  Prospective Studies  Time Factors  CLINICAL
       TRIAL  JOURNAL ARTICLE  MULTICENTER STUDY  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).